24/7 Market News Snapshot 27 August, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

August 27, 2025

DENVER, Colo., 27 August, 2025 (www.247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical enterprise focused on developing targeted immunotherapies for cancer, announced a significant rise in its stock price, opening at $1.66 and currently trading at $1.705, an increase of approximately 10.71%. This upward momentum follows a prior session closing at $1.54 and is underscored by a trading volume of 847.42K, reflecting heightened investor interest. The potential for further growth remains, with a breakout above $1.70 likely to attract additional buyers, while resistance levels are observed at $1.80 and $2.00. Should the price retract, it may find support around $1.60.

In tandem with this positive market trend, MAIA revealed the publication of a pivotal manuscript from its Phase 2 THIO-101 clinical trial in the prestigious peer-reviewed journal Cells. The research, entitled “Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy,” showcases the collective efforts of oncology researchers from MAIA and multiple institutions. Key figures include Dr. Sergei Gryaznov, Chief Scientific Officer, and Dr. Ilgen Mender, Director of Biology Research, alongside members of the Scientific Advisory Board, Dr. Z. Gunnur Dikmen and Dr. Saadettin Kiliçkap.

Vlad Vitoc, M.D., Chairman and CEO of MAIA, highlighted the critical importance of the findings, stating that despite advancements in immunotherapy, many patients struggle with resistance issues. The innovative approach of combining ateganosine with a checkpoint inhibitor demonstrates promising therapeutic potential in a patient population experiencing significant unmet medical needs.

Ateganosine, the company’s investigational treatment, targets telomeres in non-small cell lung cancer (NSCLC), showing promise in inducing tumor regression and building immune memory. This development underscores MAIA’s commitment to advancing cancer therapies, aiming to improve and extend the lives of patients facing this challenging disease.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.